Krystal Biotech, Inc., the leader in redosable gene therapy, announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) for the treatment of patients with dystrophic epidermolysis bullosa (DEB).
B-VEC is an investigational non-invasive, topical gene therapy designed to treat DEB at the molecular level by providing the patient
